开发和描述纳米结构脂质载体配方的新组合和组合,载有转白,用于肺部药物输送
Iftikhar Khan1, Sunita Sunita1, Nozad R Hussein2
1School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK.
Pharmaceutics
|January 8, 2025
概括
这项研究开发了优化纳米结构脂质载体 (NLCs) 用于转白醇 (TRES) 肺部输送. 使用喷气式雾化剂的F14配方显示出用于癌症治疗的优异气溶和药物沉积.
科学领域:
- 纳米技术 纳米技术
- 制药科学 制药科学
- 药物运输 药物运输 药物运输
背景情况:
- 肺部药物输送为肺部疾病提供有针对性的治疗.
- 纳米结构脂质载体 (NLCs) 是增强药物疗效的有希望的载体.
- 转白醇 (TRES) 具有抗癌性质,但需要有效的输送系统.
研究的目的:
- 为了制造和优化TRES载荷的NLCs通过雾化进行肺部输送.
- 描述开发的NLC配方的物理化学特性和稳定性.
- 为了评估优化的NLC配方的气溶性能和药物沉积.
主要方法:
- 通过使用各种脂质和表面活性剂组合的热,高压均质化来制备NLC.
- 配方被选为颗粒大小,多分散度指数 (PDI) 和捕获效率.
- 优化的配方 (F14) 经过稳定性测试和使用喷气式和超声波雾化器的气溶化研究.
主要成果:
- 准备了24种TRES-NLC配方;F14表现出最佳的物理化学特性 (颗粒大小<145nm,PDI<0.21,捕获效率>96%).
- 配方F14表现出极好的稳定性六个月和优越的气溶性能与空气喷射雾化器.
- 观察到F14的药物沉积量很高,在酸盐缓冲区 (pH 5.4) 中累计释放95% (pH 5.4).
结论:
- 优化的TRES-NLC配方 (F14) 与喷气式雾化器相结合,对肺部药物输送非常有效.
- 这种组合显示出更高的发射剂量 (ED),细颗粒剂量 (FPD) 和可呼吸分数 (RF).
- 这些发现凸显了NLCs在向肺部输送抗癌剂方面的潜力.
相关概念视频
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


